Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: A multicenter, randomized, double-dummy study

Clinical Therapeutics

Volumn 23, Issue 5, 2001, Pages 761-770

  Luzza, Francesco ^a   Giglio, Andrea ^b   Ciliberto, Enrico ^c   Belmonte, Angelo ^d   Cavaliere, Cesare ^a   Saccà, Natale ^b   Frandina, Chiara ^c   Fiocca, Roberto ^e   Trimboli, Vincenzo ^d   Pallone, Francesco ^f  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c Ospedale San Giovanni di Dio   (Italy)

^d Ospedale Annunziata   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Duodenal ulcer; Gastritis; Helicobacter pylori; Lansoprazole; Ranitidine bismuth citrate

Indexed keywords

CLARITHROMYCIN; LANSOPRAZOLE; RANITIDINE BISMUTH CITRATE; TINIDAZOLE;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT FAILURE; TREATMENT OUTCOME; ULCER HEALING;

EID: 0035007924     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80025-4     Document Type: Article

References (15)

1. 1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease, JAMA. 1994;272;65-69.
2. 2. Greenberg PD, Koch J, Cello JP. Clinical utility and cost effectiveness of Helicobacter pylori testing for patients with duodenal and gastric ulcers. Am J Gastroenterol. 1996;91:228-232.
3. 3. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut. 1997;41:8-13.
4. 4. Ciociola AA, Webb DD, Turner K. Dual and triple therapy regimens of antisecretory agents and antibiotics for the eradication of Helicobacter pylori: An overview. Scand J Gastroenterol Suppl. 1996;218:3-9.
5. 5. Peterson WL, Ciociola AA, Sykes DL, et al, for the RBC H pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H pylori and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10:251-261.
6. 6. Wyeth JW, Pounder RE, Duggan AE, et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996; 10:623-630.
7. 7. Axon AT, Ireland A, Smith MJ, Rooprams PD. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1997;11:81-87.
8. 8. Bardhan KD, Wurzer H, Marcelino M, et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. Am J Gastroenterol. 1998; 93:380-385.
9. 9. Bardhan KD, Dallaire C, Eisold H, Duggan AE. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal Ulcer. Gut. 1997;41:181-186.
10. 10. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive, functional dyspepsia. Gastroenterology. 1994;106: 1174-1183.
11. 11. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
12. 12. Howden CW, Hunt RH, for the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol. 1998;93:2330-2338.
13. 13. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493-496.
14. 14. Williamson R, Pipkin GA, Wood JR. New options in Helicobacter pylori eradication: Efficacy, resistance, and synergy. Scand J Gastroenterol Suppl. 1998;225: 36-40.
15. 15. Lerang F, Mourn B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: Does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol. 1997;92:248-253.